Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: correlations with CSF HVA.
CSF somatostatin and homovanillic acid (HVA) were measured in 14 schizophrenic patients while they were drug-free and during chronic fluphenazine treatment. CSF somatostatin was significantly reduced and CSF HVA was significantly elevated (p less than 0.002) during fluphenazine treatment. There was a trend toward correlation between CSF somatostatin and CSF HVA in the 14 schizophrenic patients when drug-free (r = 0.49, p less than 0.07) and fluphenazine-treated (r = 0.47, p less than 0.08). When examined in a larger group (n = 46) of drug-free schizophrenics, this relationship was highly significant (r = 0.59, p less than 0.001). These clinical data are consistent with preclinical evidence indicating a functional interaction between CNS somatostatin and dopamine systems.
Doran
A R
AR
Clinical Neuroscience Branch, National Institute of Mental Health, Bethesda, MD 20892.
Rubinow
D R
DR
Wolkowitz
O M
OM
Roy
A
A
Breier
A
A
Pickar
D
D
D000328:Adult; D001921:Brain / Q000187:drug effects; D002986:Clinical Trials as Topic; D005260:Female; D005476:Fluphenazine / Q000627:therapeutic use*; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid*; D006801:Humans; D008297:Male; D012559:Schizophrenia / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D013004:Somatostatin / Q000134:cerebrospinal fluid*
D013004:Somatostatin; D005476:Fluphenazine; D006719:Homovanillic Acid